ZIMMER BIOMET HOLDINGS, INC. ZBH

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical Appliance and Supplies Manufacturing derived NYSE

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We design, manufacture and market orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic ("CMFT") products; bone cement; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives. In this report, "Zimmer Biomet," "we," "us," "our," "the Company" and similar words refer collectively to Zimmer Biomet Holdings, Inc. and its subsidiaries. "Zimmer Biomet Holdings" refers to the parent company only.

Last close 98.56 2026-10-23
Market cap $18.80B 2026-06-30 share count
52-week range 79.12 - 103.70

Valuation FY2025 figures against the last close

P/S2.3x
P/E27.8x
P/FCF12.8x
EV/EBITDA11.7x
Dividend yield1.0%
Diluted EPS3.55

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • US
  • International
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2025 US, FY2025: 4.8B (57.9%) 58% US International, FY2025: 3.5B (42.1%) 42% International FY2024 US, FY2024: 4.4B (57.8%) 58% International, FY2024: 3.2B (42.2%) 42% FY2023 US, FY2023: 4.3B (58.0%) 58% International, FY2023: 3.1B (42.0%) 42%
Region FY2025FY2024FY2023
US $4.76B $4.44B $4.29B
International $3.47B $3.24B $3.11B

As the company reported it, from the “Revenue Recognition - Schedule of Net Sales by Geography (Detail)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $8.23B$7.68B$7.39B$6.94B$6.83B$6.13B$6.96B$7.93B$7.80B$7.67B
Cost of revenue $2.49B$2.19B$2.08B$2.02B$1.96B$1.82B$1.94B$2.27B$2.13B$2.38B
Gross profit $5.74B$5.49B$5.31B$4.92B$4.87B$4.30B$5.02B$5.66B$5.67B$5.29B
SG&A $3.26B$2.93B$2.84B$2.76B$2.84B$2.71B$2.81B$3.38B$3.10B$2.94B
Total operating expenses $7.13B$6.39B$6.12B$6.24B$5.97B$6.04B$5.85B$7.90B$7.00B$6.85B
Operating income $1.10B$1.29B$1.28B$696.3M$860.3M$83.1M$1.11B$33.8M$799.3M$821.1M
Interest expense $292.8M$218.0M$201.2M$164.8M$208.4M$212.1M$227.0M$289.3M$325.3M$355.0M
Pre-tax income $830.8M$1.04B$1.07B$403.5M$499.0M-$105.2M$880.1M-$271.1M$464.6M$399.6M
Income tax $125.7M$131.4M$42.2M$112.3M$53.5M$96.0M$238.0M$108.2M$1.35B$95.0M
Net income $705.1M$903.8M$1.02B$231.4M$401.6M-$138.9M$1.13B-$379.2M$1.81B$305.9M
EPS, basic 3.564.454.911.101.93-0.675.52-1.868.981.53
EPS, diluted 3.554.434.881.101.91-0.675.47-1.868.901.51
Shares, diluted (wtd. avg.) 198.7M203.9M209.7M210.3M210.4M207.0M206.7M203.5M203.7M202.4M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $591.9M$525.5M$415.8M$375.7M$378.1M$802.1M$617.9M$542.8M$524.4M$634.1M
Receivables $1.70B$1.48B$1.44B$1.38B$1.26B$1.45B$1.36B$1.28B$1.54B$1.60B
Inventory $2.29B$2.24B$2.39B$2.15B$2.15B$2.45B$2.38B$2.26B$2.07B$1.96B
Total current assets $5.12B$4.67B$4.61B$4.43B$4.88B$5.08B$4.72B$4.43B$4.56B$4.66B
Property, plant and equipment $2.21B$2.05B$2.06B$1.87B$1.84B$2.05B$2.08B$2.02B$2.04B$2.04B
Goodwill $9.95B$8.95B$8.82B$8.58B$8.92B$8.98B$9.60B$9.59B$10.67B$10.64B
Other intangibles $4.72B$4.60B$4.86B$5.06B$5.53B$7.06B$7.26B$7.68B$8.35B$8.79B
Total assets $23.09B$21.37B$21.50B$21.07B$23.46B$24.42B$24.64B$24.13B$26.01B$26.68B
Accounts payable $303.0M$194.6M$410.6M$354.1M$306.5M$330.0M$400.9M$362.6M$330.2M$364.5M
Short-term debt $587.1M$863.0M$900.0M$544.3M$1.61B$500.0M$1.50B$525.0M$1.23B$575.6M
Total current liabilities $2.58B$2.45B$2.86B$2.36B$3.47B$2.56B$3.44B$2.42B$3.07B$2.38B
Long-term debt $6.93B$5.34B$4.87B$5.15B$1.00B$7.63B$6.72B$8.41B$8.92B$10.67B
Total liabilities $10.39B$8.89B$9.01B$9.04B$10.79B$12.22B$12.25B$12.85B$14.28B$17.01B
Retained earnings $11.61B$11.10B$10.38B$9.56B$10.29B$10.09B$10.43B$9.49B$10.02B$8.47B
Total equity $12.70B$12.47B$12.49B$12.03B$12.67B$12.20B$12.39B$11.28B$11.74B$9.67B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $1.70B$1.50B$1.58B$1.36B$1.40B$1.08B$1.39B$1.75B$1.58B$1.63B
Depreciation and amortisation $1.09B$996.3M$951.7M$926.4M$937.7M$898.4M$871.0M$1.04B$1.06B$1.04B
Stock-based compensation $90.2M$101.0M$99.8M$105.0M$76.0M$73.8M$77.2M$65.5M$53.7M$57.3M
Capital expenditure $224.5M$203.8M$291.1M$187.9M$143.6M$111.9M$198.4M$162.7M$156.0M$184.7M
Investing cash flow -$1.98B-$888.1M-$778.9M-$522.0M-$443.3M-$564.3M-$644.7M-$416.6M-$510.8M-$1.69B
Financing cash flow $326.0M-$484.5M-$763.5M-$775.7M-$1.31B-$420.2M-$777.6M-$1.30B-$1.21B-$743.2M
Dividends paid $190.3M$196.0M$200.9M$201.2M$200.1M$198.5M$196.7M$195.2M$193.6M$188.4M
Buybacks $487.0M$868.0M$692.2M$126.4M—————$415.5M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-059853.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -2.5B 0 2.5B 5B 7.5B 10B Revenue, FY2016: 7.7B Gross profit, FY2016: 5.3B Net income, FY2016: 305.9M Revenue, FY2017: 7.8B Gross profit, FY2017: 5.7B Net income, FY2017: 1.8B Revenue, FY2018: 7.9B Gross profit, FY2018: 5.7B Net income, FY2018: -379.2M Revenue, FY2019: 7B Gross profit, FY2019: 5B Net income, FY2019: 1.1B Revenue, FY2020: 6.1B Gross profit, FY2020: 4.3B Net income, FY2020: -138.9M Revenue, FY2021: 6.8B Gross profit, FY2021: 4.9B Net income, FY2021: 401.6M Revenue, FY2022: 6.9B Gross profit, FY2022: 4.9B Net income, FY2022: 231.4M Revenue, FY2023: 7.4B Gross profit, FY2023: 5.3B Net income, FY2023: 1B Revenue, FY2024: 7.7B Gross profit, FY2024: 5.5B Net income, FY2024: 903.8M Revenue, FY2025: 8.2B Gross profit, FY2025: 5.7B Net income, FY2025: 705.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $7.67B $7.80B $7.93B $6.96B $6.13B $6.83B $6.94B $7.39B $7.68B $8.23B
Gross profit $5.29B $5.67B $5.66B $5.02B $4.30B $4.87B $4.92B $5.31B $5.49B $5.74B
Net income $305.9M $1.81B -$379.2M $1.13B -$138.9M $401.6M $231.4M $1.02B $903.8M $705.1M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $159.78B 57.5x 20.5%
EW Edwards Lifesciences Corp $51.34B 48.7x 11.5%
STE STERIS plc $22.63B 29.3x 8.7%
ALGN ALIGN TECHNOLOGY INC $10.98B 27.3x 0.9%
MSA MSA Safety Inc $7.03B 25.7x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $1.90B — 27.1%
CDRE Cadre Holdings, Inc. $1.28B 29.4x 7.5%
ENOV Enovis CORP $1.22B — 6.7%